About OPT Congress: Discover, Develop and Deliver Next-Generation Nucleic Acids
OPT Congress is where the global oligonucleotide and RNA community comes together to explore the science, technologies, and strategies shaping the future of nucleic acid therapeutics. Bringing together researchers, drug developers, technology innovators, and industry leaders, the congress spans the entire development continuum—from target discovery and therapeutic design through clinical development, CMC, formulation, manufacturing, and commercialization. With four dedicated conference tracks - Oligo Discovery & Clinical Development, Targeted Oligo Delivery Using Conjugates, mRNA & Emerging Nucleic Acid Modalities and Oligo CMC, Analytics & Manufacturing — the event provides a one-stop-shop for focused scientific content while fostering the collaboration that drives innovation.
Designed to address both today's challenges and tomorrow's opportunities, OPT Congress features expert-led presentations, dynamic panel discussions, interactive breakout discussions, poster presentations, networking opportunities, and in-depth short courses. Whether you are discovering novel therapeutic targets, moving candidates through the clinic, scaling manufacturing, or pioneering emerging modalities, OPT Congress delivers practical insights, real-world case studies, and valuable connections to help streamline development and bring the next generation of nucleic acid medicines to patients.
Top Reasons to Attend
Hear from the pioneers shaping the future of nucleic acid therapeutics
Gain insights from world-renowned academics, biopharmaceutical leaders, technology innovators, and regulatory experts as they present the latest scientific breakthroughs and strategies advancing oligonucleotide therapeutics, targeted delivery technologies, mRNA, and emerging nucleic acid modalities.
Explore four focused conferences covering the full development lifecycle
Customize your agenda across four expertly curated conference tracks: Oligo Discovery & Clinical Development, Oligo CMC, Analytics & Manufacturing, Targeted Oligo Delivery Using Conjugates, and mRNA & Emerging Nucleic Acid Modalities. With on-demand access included, you can explore cutting-edge science across the entire nucleic acid therapeutic landscape.
Discover practical solutions from real-world case studies
Learn how leading organizations are overcoming challenges in therapeutic design, clinical translation, targeted delivery, formulation, analytical characterization, manufacturing, regulatory strategy, and commercialization. Hear lessons learned from early discovery through clinical development and beyond.
Stay at the forefront of scientific innovation
Explore the latest advances in linker-payload chemistries, conjugate-enabled delivery, extrahepatic targeting, endosomal escape, novel oligonucleotide chemistries, AI-enabled drug discovery, RNA editing, circular and self-amplifying RNA, and the next generation of nucleic acid therapeutics transforming the field.
Build your expertise through interactive short courses
Strengthen your technical and regulatory knowledge with expert-led, in-depth training designed to complement the conference program. Gain practical guidance on the unique challenges of nucleic acid therapeutic development, from safety and toxicology to CMC, manufacturing, quality, and successful regulatory submissions.
Connect with the leaders driving the industry forward
OPT Congress is intentionally designed to foster meaningful connections. In an environment where it's easy to meet the right people, you'll network with preclinical and drug development scientists, CMC and manufacturing experts, regulatory authorities, technology developers, investors, and business development professionals through dedicated networking events, panel discussions, poster sessions, and informal meet-ups that spark collaboration long after the Congress ends.
Discover the technologies accelerating therapeutic development
Meet innovative technology providers, CROs, CDMOs, instrumentation companies, and solution partners showcasing the latest platforms and services supporting oligonucleotide discovery, targeted delivery, formulation, manufacturing, analytical characterization, and next-generation nucleic acid therapeutics.